MAP2K1 and Langerhans cell histiocytosis: Elevated NLR, PLR, SII, BRAF V600E, SIRI, and MAP2K1 mutations predicted inferior PFS, OS and worse treatment efficacy after a 6-week treatment, and the new risk model could be used for stratifying patients with LCH into various risk categories for prognostic prediction.